Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn112140-20190923-00605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced liver injury related to avacopan therapy.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan.
Objectives: The efficacy of avacopan as remission induction therapy for Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (AAV) is well-established. However, concerns regarding liver injury post-avacopan treatment remain, especially in Japan. Therefore, this study aimed to investigate drug-induced liver injury (DILI) associated with avacopan treatment.
View Article and Find Full Text PDFVanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury.
BMJ Case Rep
November 2024
Essentia Health Fargo Hospital, Fargo, North Dakota, USA.
Temozolomide (TMZ)-levetiracetam (LEV) combination therapy in glioblastoma management is gradually becoming a mainstay treatment given its superior effect compared with TMZ monotherapy. While there have been previous cases of hepatotoxicity, there are no prior reports of vanishing bile duct syndrome (VBDS) associated with TMZ-LEV combination use. This case report details a male in his 50s who had recently completed TMZ and LEV for right frontal lobe glioblastoma.
View Article and Find Full Text PDFDrug-induced cholestatic liver diseases.
Hepatology
August 2024
Department of Gastroenterology and Hepatology, St. John's Medical College Hospital, Bangalore, India.
Cholestatic DILI is an important and frequently challenging differential diagnosis in patients presenting with elevated liver tests with predominant elevation in alkaline phosphatase. A number of competing etiologies need to be ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms of viral hepatitis, cholestasis of sepsis, primary and secondary cholangitis, and right-sided cardiac failure to name a few. Important advances have occurred in the understanding and knowledge of the clinical phenotypes, new etiological agents, risk factors, pathophysiology, and genetic determinants of drug-induced cholestasis since the last review on drug-induced cholestasis was published in Hepatology in 2011.
View Article and Find Full Text PDFGlucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.
Mol Biol Rep
July 2024
State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.
Drug-induced liver injury (DILI) is an adverse reaction to drugs and their metabolites. The activation of adaptive immune and inflammatory responses plays an important role in the pathogenesis of DILI. Glucocorticoids (GCs) have powerful anti-inflammatory and immunosuppressive effects and have been used to treat a variety of immune-mediated liver diseases.
View Article and Find Full Text PDFAcquired ductopenia: an insight into imaging findings.
Abdom Radiol (NY)
July 2024
Division of Abdominal Imaging, Department of Radiology, Mayo Clinic, Scottsdale, AZ, USA.
Hepatic ductopenia is a pathologic diagnosis characterized by a decrease in the number of intrahepatic bile ducts as a consequence of various underlying etiologies. Some etiologies, such as primary sclerosing cholangitis, primary biliary cholangitis, and ischemic cholangitis, often have distinctive imaging findings. In contrast, other causes such as chronic rejection following liver transplantation, drug-induced biliary injury, infection, malignancy such as lymphoma, and graft-versus-host disease may only have ancillary or non-specific imaging findings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!